Full-Time

Vice President Neuroscience

Neuroscience

Arvinas

Arvinas

201-500 employees

Clinical-stage biopharma developing PROTAC degraders

No salary listed

No H1B Sponsorship

New Haven, CT, USA

Hybrid

Three or more days on-site per week at the New Haven headquarters.

PhD

Category
Biology & Biotech (1)

Get referred to Arvinas

See people who can refer or advise you

Requirements
  • Ph.D., with 15+ years of industry/ biotech leadership experience in neurobiology and pharmacology with clear contributions to clinical candidates.
  • Must be authorized to work in the United States without current or future employer-sponsored visa sponsorship.
  • Established scientific reputation in neuroscience and neurodegenerative disease research, with extensive experience applying quantitative and statistical approaches to evaluate disease-relevant in vivo models and translational biomarker endpoints.
  • Recognized leader with a strong track record of initiating and cultivating high-value collaborations with academic thought leaders, research consortia, CROs, foundations, and patient advocacy groups to drive scientific innovation, translational research, and therapeutic development in neurodegenerative diseases.
  • Leader with extensive experience building and leading multidisciplinary teams focused on preclinical pharmacology and translational medicine, leveraging disease-relevant models and human biomarker data to drive critical development decisions and advance neuroscience programs from discovery through clinical proof of concept.
Responsibilities
  • Leads the neuroscience organization with bold new vision, clarity, purpose, and scientific excellence, fostering a culture of innovation and collaboration while advancing and prioritizing high-impact programs from discovery through clinical development.
  • Builds, leads and inspires a high-performing team through mentorship and development of leadership, scientific and technical capabilities.
  • Enables the team to identify, develop, and apply relevant preclinical in vivo models to support target validation, lead identification, and optimization. Uses a deep understanding of disease and target biology to guide key scientific decisions and oversees the development of robust target engagement, pathway biology, and biomarker assays that support preclinical pharmacology and translational research.
  • Provides strategic oversight for the design, execution, and interpretation of preclinical pharmacology studies to characterize compound activity, establish pharmacokinetic/pharmacodynamic (PK/PD) relationships, and guide candidate optimization. Leverages study outcomes to support translational strategies, inform human dose projections, and advance programs toward clinical development.
  • Collaborates cross-functionally with Research, Translational Sciences, Clinical Development, Regulatory, and Biometrics leaders to define and execute integrated development strategies across the neuroscience portfolio.
  • Establishes and leads strategic collaborations with biopharma partners, key scientific investigators, contract research organizations, academic institutions, and external partners to advance translational neuroscience, induced pluripotent stem cell models, biomarker assay capabilities, including assay transfer, method development, qualification, validation, and clinical implementation.
  • Provides scientific leadership and strategic oversight for the generation, interpretation, and communication of preclinical pharmacology and translational data to support regulatory submissions, including INDs, CTAs, Investigator Brochures, clinical study protocols, study reports, and laboratory manuals.
  • Collaborates across research and development functions to define program strategy, drive execution, and accelerate pipeline progression, leveraging high-quality in vivo pharmacology, biomarker, and translational data to support critical development and portfolio decisions.
  • Provides leadership, mentorship, and talent development across the neuroscience organization, fostering a culture of collaboration, trust, accountability, and scientific excellence that enables teams to achieve their highest potential.

Arvinas develops PROTAC-based protein degraders in clinical-stage biopharmaceutical programs aimed at diseases driven by harmful proteins, including cancer and neurodegenerative disorders. Its PROTAC platform works by linking a disease-causing protein to an E3 ligase, tagging the target for degradation by the cell’s proteasome rather than merely inhibiting it. Revenue comes from partnerships, collaborations, and licensing deals with other pharma companies, as well as the potential commercialization of its drug candidates. The company’s goal is to improve patient outcomes by delivering targeted, mechanism-based therapies and advancing its drug candidates through discovery, development, and potential commercialization.

Company Size

201-500

Company Stage

IPO

Headquarters

New Haven, Connecticut

Founded

2013

Get referred to Arvinas

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $249.7 million from VEPPANU licensing and Pfizer deferred revenue.
  • Cash and marketable securities totaled $567.9 million on June 30, 2026, funding 2028.
  • Arvinas expects ARV-393, ARV-027, and ARV-102 data catalysts across 2026-2027.

What critics are saying

  • ARV-102 remains on U.S. clinical hold pending toxicology, delaying neurology trials into 2027.
  • Randy Teel replaced John Houston in February 2026, signaling execution pressure after repeated restructurings.
  • If ARV-393 and ARV-027 disappoint, Arvinas becomes a single-partnered royalty story.

What makes Arvinas unique

  • First FDA-approved PROTAC VEPPANU validated Arvinas' degrader platform and boosted partner interest.
  • Deep pipeline spans oncology and neurology: ARV-393, ARV-027, ARV-102, ARV-806.
  • Rigel's 2026 launch and Pfizer collaboration prove pharma trusts Arvinas' chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Arvinas shifts focus to Phase I programmes after first PROTAC degrader approval

Arvinas reported progress on several strategic initiatives during its second quarter 2026 earnings call. The company achieved three key milestones this year: securing the first FDA approval for a PROTAC degrader, VEPPANU; completing an out-licensing deal for VEPPANU with Rigel Pharmaceuticals; and deciding to advance its KRAS G12D programme, ARV-806, only through a partnership. President and Chief Executive Officer Randy Teel said the company is focusing on advancing transformational improvements for patients through continued innovation and disciplined execution. The strategic decisions have positioned Arvinas to concentrate fully on its Phase I clinical programmes in oncology and neurology. The company determined that ARV-806 requires investment inconsistent with its current capital allocation strategy, though it believes the programme has potential as a meaningful treatment option.

Yahoo Finance
Aug 4th, 2026
Arvinas secures first FDA approval for PROTAC degrader, shifts focus to oncology and neurology pipelines

Arvinas has achieved the first-ever FDA approval of a PROTAC degrader, VEPPANU, validating its protein degradation platform. The company has out-licensed VEPPANU to Rigel Pharmaceuticals for $249.7 million and shifted focus to Phase I oncology and neurology programmes. The company will only advance its KRAS G12D programme through a partnership. Initial Phase I data for ARV-393 (BCL6) is expected by year-end 2026, whilst proof-of-mechanism data for ARV-027 is anticipated in the first half of 2027. Arvinas established a $52.7 million liability to cover remaining VEPPANU development obligations. Non-GAAP R&D expenses decreased 14% year-over-year following 2025 cost-reduction programmes. The company maintains a cash runway extending into the second half of 2028. ARV-102 faces a technical clinical hold in the US pending additional toxicology data.

Yahoo Finance
Aug 4th, 2026
Arvinas shifts to early-stage pipeline after FDA approves first PROTAC degrader VEPPANU

Arvinas is redirecting resources to early-stage oncology and neurology programmes following FDA approval of VEPPANU, the first PROTAC degrader, which was licensed to Rigel Pharmaceuticals. The company's KRAS G12D programme, ARV-806, will only progress through a partner. Key clinical catalysts are expected for ARV-393 in lymphoma by year-end 2026, ARV-027 in spinal and bulbar muscular atrophy in the first half of 2027, and ARV-102 trials in neurodegenerative disease beginning in 2027. Arvinas reported $249.7 million in second-quarter revenue, including licence and milestone payments tied to VEPPANU. Cash and marketable securities totalled $567.9 million at 30 June, with management maintaining a cash runway into the second half of 2028.

Yahoo Finance
Aug 4th, 2026
Arvinas secures first-ever PROTAC regulatory approval, out-licenses VEPPANU to Rigel Pharmaceuticals

Arvinas secured the first regulatory approval for a PROTAC protein degrader with VEPPANU and licensed it to Rigel Pharmaceuticals. The treatment is approved for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. The company expects to share clinical data from three Phase 1 programmes — ARV-393, ARV-102, and ARV-027 — over the next 12 months. Arvinas is initiating a Phase 1 trial for ARV-6723, an HPK1 degrader showing single-agent activity in preclinical models. The National Comprehensive Cancer Network added VEPPANU to its clinical practice guidelines for breast cancer as a Category 2A treatment option.

Associated Press
Aug 4th, 2026
Arvinas secures first-ever PROTAC approval, licenses VEPPANU to Rigel Pharmaceuticals

Arvinas reported second quarter 2026 financial results, highlighting VEPPANU's approval as the first-ever PROTAC protein degrader therapy and its subsequent out-licensing to Rigel Pharmaceuticals. The company plans to share clinical data from three Phase 1 programmes over the next 12 months. As of 30 June 2026, Arvinas held $567.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at year-end 2025. The company expects these funds to sustain operations into the second half of 2028. Second quarter revenue reached $249.7 million, compared with $22.4 million in the same period last year. The increase was primarily driven by recognition of deferred revenue from its Pfizer collaboration and $62.5 million from the Rigel licence agreement. Research and development expenses decreased to $52.6 million from $68.6 million year-over-year.